Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical firm dedicated to developing innovative cancer treatments, announced its participation in the 19th Annual LD Micro Main Event. The event will take place on October 21 at 11:30 AM PT at the Hotel del Coronado in San Diego, California. Vuong Trieu, Ph.D., serving as CEO, will lead the presentation.
Chris Lahiji, the founder of LD Micro, expressed enthusiasm for the event, stating, “The Main Event is a culmination of over 25 years of hard work and passion for small company investing. There is no organization on planet Earth that cares more about small companies succeeding than LD. To be able to connect with our community in one of the most beautiful settings imaginable brings me considerable joy. We look forward to welcoming all of our patrons and ensuring that they have a wonderful time.”
Dr. Trieu highlighted Oncotelic”s commitment to utilizing its extensive knowledge of the tumor microenvironment to enhance various oncology drug candidates. He noted the significant progress made in their lead program, Sapu, which is a joint venture in which Oncotelic holds a 45% stake. The company is eager to share updates on its advancements as it approaches critical milestones in formulation optimization, regulatory interactions, and clinical trials.
The LD Micro Main Event XIX will unfold from October 19 to 21 at the Hotel del Coronado. The first day includes registration and keynote speakers, complemented by stunning views of the Pacific Ocean. This will be followed by two days filled with company presentations and individualized meetings with investors, culminating in a closing reception. Approximately 120 companies are expected to participate, presenting in half-hour intervals and engaging in private meetings with investors.
Oncotelic Therapeutics, formerly known as Mateon Therapeutics, Inc., was established in New York in 1988 under the name OXiGENE, Inc.. It underwent reincorporation in Delaware in 1992 and rebranded in 2016. The company aims to leverage its expertise in oncology drug development to enhance treatment outcomes for cancer patients, particularly focusing on rare pediatric cancers. Oncotelic holds rare pediatric designations for conditions such as Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503.
In addition, Oncotelic acquired PointR Data Inc. in November 2019 and AL-101 during the fourth quarter of 2021, which is intended for the intranasal delivery of apomorphine to treat Parkinson”s Disease. With over 60,000 new diagnoses annually in the U.S. and an expectation of 1.2 million patients by 2030, the need for effective treatments is pressing. Furthermore, AL-101 is being developed for Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD), addressing a significant gap in treatment options for both conditions.
This press release may contain forward-looking statements as defined by the Securities Act and the Exchange Act, encompassing substantial risks and uncertainties. The company identifies forward-looking statements through terms like “may,” “will,” “expect,” and similar expressions.
For further inquiries regarding Oncotelic Therapeutics, please contact their investor relations at [email protected].
